Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response

被引:150
作者
Lemonde, S
Du, LS
Bakish, D
Hrdina, P
Albert, PR
机构
[1] Univ Ottawa, Dept Med & Cellular & Mol Med, Ottawa Hlth Res Inst, Ottawa, ON K1H 8M5, Canada
[2] Royal Ottawa Hosp, Mental Hlth Res Inst, Ottawa, ON K1Z 7K4, Canada
关键词
flibanserin; mutation; pharmacogenetics; transcription;
D O I
10.1017/S1461145704004699
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Antidepressants, such as serotonin or noradrenaline reuptake inhibitors (e.g. fluoxetine, nefadozone) or 5-HT1A agonists (flibanserin), desensitize the 5-HT1A autoreceptor, which may contribute to their clinical efficacy. The 5-HT1A receptor gene is repressed by NUDR/DEAF-1 in raphe cells at the C-, but not at the G-allele of the C(-1019)G polymorphism that is associated with major depression and suicide. Depressed patients (n = 118) were treated with antidepressants including fluoxetine or nefadozone combined with pindolol or flibanserin alone. The severity of depression was assesssed using the Hamilton Rating Scale for Depression. Although patients had similar severity initially, those with the homozygous C(-1019) genotype responded significantly less to flibanserin ( p = 0.039) and in pooled antidepressant treatment groups (p = 0.0497) and were approximately twice as likely to be non-responders as those with the C(-1019)C genotype. These results implicate the C(-1019)G 5-HT1A gene polymorphism as a potential marker for antidepressant response, suggesting a role for repression of the 5-HT1A gene.
引用
收藏
页码:501 / 506
页数:6
相关论文
共 26 条
[1]  
[Anonymous], 1994, AM PSYCHIATR ASSOC
[2]   Analysis of structural polymorphisms and C-1018G promoter variant of the 5-HT1A receptor gene as putative risk factors in major depression (vol 7, pg 930, 2003) [J].
Arias, B ;
Arranz, MJ ;
Gasto, C ;
Catalan, R ;
Pintor, L ;
Gutierrez, B ;
Kerwin, RW ;
Fananas, L .
MOLECULAR PSYCHIATRY, 2003, 8 (02) :246-246
[3]   Analysis of structural polymorphisms and C-1018G promoter variant of the 5-HT1A receptor gene as putative risk factors in major depression [J].
Arias, B ;
Arranz, MJ ;
Gasto, C ;
Catalan, R ;
Pintor, L ;
Gutierrez, B ;
Kerwin, RW ;
Fananas, L .
MOLECULAR PSYCHIATRY, 2002, 7 (09) :930-932
[4]   Fast onset: An open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy [J].
Bakish, D ;
Hooper, CL ;
Thornton, MD ;
Wiens, A ;
Miller, CA ;
Thibaudeau, CA .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1997, 12 (02) :91-97
[5]   Is there a role for 5-HT1A agonists in the treatment of depression? [J].
Blier, P ;
Ward, NM .
BIOLOGICAL PSYCHIATRY, 2003, 53 (03) :193-203
[6]  
Du LS, 2000, AM J MED GENET, V96, P56, DOI 10.1002/(SICI)1096-8628(20000207)96:1<56::AID-AJMG12>3.0.CO
[7]  
2-L
[8]   Major depressive disorder [J].
Fava, M ;
Kendler, KS .
NEURON, 2000, 28 (02) :335-341
[9]  
Gobbi G, 2001, J PHARMACOL EXP THER, V296, P987
[10]   The national depressive and manic-depressive association consensus statement on the undertreatment of depression [J].
Hirschfield, RMA ;
Keller, MB ;
Panico, S ;
Arons, BS ;
Barlow, D ;
Davidoff, F ;
Endicott, J ;
Froom, J ;
Goldstein, M ;
Horman, JM ;
Guthrie, D ;
Marek, RG ;
Maurer, TA ;
Meyer, R ;
Phillips, K ;
Ross, J ;
Schwenk, TL ;
Sharfstein, SS ;
Thase, ME ;
Wyatt, RJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (04) :333-340